Literature DB >> 24687853

p19Ink4d is a tumor suppressor and controls pituitary anterior lobe cell proliferation.

Feng Bai1, Ho Lam Chan1, Matthew D Smith2, Hiroaki Kiyokawa3, Xin-Hai Pei4.   

Abstract

Pituitary tumors develop in about one-quarter of the population, and most arise from the anterior lobe (AL). The pituitary gland is particularly sensitive to genetic alteration of genes involved in the cyclin-dependent kinase (CDK) inhibitor (CKI)-CDK-retinoblastoma protein (Rb) pathway. Mice heterozygous for the Rb mutation develop pituitary tumors, with about 20% arising from the AL. Perplexingly, none of the CKI-deficient mice reported thus far develop pituitary AL tumors. In this study, we show that deletion of p19(Ink4d) (p19), a CKI gene, in mice results in spontaneous development of tumors in multiple organs and tissues. Specifically, more than one-half of the mutant mice developed pituitary hyperplasia or tumors predominantly in the AL. Tumor development is associated with increased cell proliferation and enhanced activity of Cdk4 and Cdk6 and phosphorylation of Rb protein. Though Cdk4 is indispensable for postnatal pituitary cell proliferation, it is not required for the hyperproliferative pituitary phenotype caused by p19 loss. Loss of p19 phosphorylates Rb in Cdk4(-/-) pituitary AL cells and mouse embryonic fibroblasts (MEFs) and rescues their proliferation defects, at least partially, through the activation of Cdk6. These results provide the first genetic evidence that p19 is a tumor suppressor and the major CKI gene that controls pituitary AL cell proliferation.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24687853      PMCID: PMC4054302          DOI: 10.1128/MCB.01363-13

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  56 in total

1.  Monoclonal antibodies specific for underphosphorylated retinoblastoma protein identify a cell cycle regulated phosphorylation site targeted by CDKs.

Authors:  T Zarkowska; S U; E Harlow; S Mittnacht
Journal:  Oncogene       Date:  1997-01-16       Impact factor: 9.867

2.  Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation.

Authors:  M Woloschak; A Yu; K D Post
Journal:  Mol Carcinog       Date:  1997-08       Impact factor: 4.784

3.  RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/- mice.

Authors:  A Y Nikitin; M I Juárez-Pérez; S Li; L Huang; W H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

4.  Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome.

Authors:  P Zhang; N J Liégeois; C Wong; M Finegold; H Hou; J C Thompson; A Silverman; J W Harper; R A DePinho; S J Elledge
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

5.  Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging.

Authors:  F Zindy; D E Quelle; M F Roussel; C J Sherr
Journal:  Oncogene       Date:  1997-07-10       Impact factor: 9.867

6.  Regulation of cyclin-dependent kinase 4 during adipogenesis involves switching of cyclin D subunits and concurrent binding of p18INK4c and p27Kip1.

Authors:  D E Phelps; Y Xiong
Journal:  Cell Growth Differ       Date:  1998-08

Review 7.  The p16INK4a/CDKN2A tumor suppressor and its relatives.

Authors:  M Ruas; G Peters
Journal:  Biochim Biophys Acta       Date:  1998-10-14

8.  A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice.

Authors:  M L Fero; M Rivkin; M Tasch; P Porter; C E Carow; E Firpo; K Polyak; L H Tsai; V Broudy; R M Perlmutter; K Kaushansky; J M Roberts
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

9.  Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1).

Authors:  H Kiyokawa; R D Kineman; K O Manova-Todorova; V C Soares; E S Hoffman; M Ono; D Khanam; A C Hayday; L A Frohman; A Koff
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

10.  CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis.

Authors:  D S Franklin; V L Godfrey; H Lee; G I Kovalev; R Schoonhoven; S Chen-Kiang; L Su; Y Xiong
Journal:  Genes Dev       Date:  1998-09-15       Impact factor: 11.361

View more
  10 in total

1.  Unexpected role for p19INK4d in posttranscriptional regulation of GATA1 and modulation of human terminal erythropoiesis.

Authors:  Xu Han; Jieying Zhang; Yuanliang Peng; Minyuan Peng; Xiao Chen; Huiyong Chen; Jianhui Song; Xiao Hu; Mao Ye; Jianglin Li; Vijay G Sankaran; Christopher D Hillyer; Narla Mohandas; Xiuli An; Jing Liu
Journal:  Blood       Date:  2016-11-22       Impact factor: 22.113

2.  Regulation of proliferation in developing human tooth germs by MSX homeodomain proteins and cyclin-dependent kinase inhibitor p19INK4d.

Authors:  Darko Kero; Katarina Vukojevic; Petra Stazic; Danijela Sundov; Snjezana Mardesic Brakus; Mirna Saraga-Babic
Journal:  Organogenesis       Date:  2017-09-21       Impact factor: 2.500

3.  Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice.

Authors:  Paraskevi Xekouki; Eva Szarek; Petra Bullova; Alessio Giubellino; Martha Quezado; Spyridon A Mastroyannis; Panagiotis Mastorakos; Christopher A Wassif; Margarita Raygada; Nadia Rentia; Louis Dye; Antony Cougnoux; Deloris Koziol; Maria de La Luz Sierra; Charalampos Lyssikatos; Elena Belyavskaya; Carl Malchoff; Jessica Moline; Charis Eng; Louis James Maher; Karel Pacak; Maya Lodish; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2015-02-19       Impact factor: 5.958

Review 4.  The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors.

Authors:  Paraskevi Xekouki; Ana Brennand; Ben Whitelaw; Karel Pacak; Constantine A Stratakis
Journal:  Horm Metab Res       Date:  2018-10-01       Impact factor: 2.936

5.  Rescue from early-onset hearing loss in a mouse model lacking the cyclin-dependent kinase inhibitor p19Ink4d.

Authors:  Q Ma; M Grati; F Bai; J Pei; X-H Pei; X Liu
Journal:  Cell Death Dis       Date:  2016-03-10       Impact factor: 8.469

6.  p16INK4a suppresses BRCA1-deficient mammary tumorigenesis.

Authors:  Alexandria Scott; Feng Bai; Ho Lam Chan; Shiqin Liu; Jinshan Ma; Joyce M Slingerland; David J Robbins; Anthony J Capobianco; Xin-Hai Pei
Journal:  Oncotarget       Date:  2016-12-20

7.  Cell cycle-independent roles of p19INK4d in human terminal erythropoiesis.

Authors:  Xu Han; Jing Liu
Journal:  Chin J Cancer       Date:  2017-02-23

8.  Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro.

Authors:  Eva Juengel; Sebastian Maxeiner; Jochen Rutz; Saira Justin; Frederik Roos; Wael Khoder; Igor Tsaur; Karen Nelson; Wolf O Bechstein; Axel Haferkamp; Roman A Blaheta
Journal:  Oncotarget       Date:  2016-12-20

Review 9.  Animal models of pituitary neoplasia.

Authors:  K E Lines; M Stevenson; R V Thakker
Journal:  Mol Cell Endocrinol       Date:  2015-08-28       Impact factor: 4.102

10.  PUMILIO proteins promote colorectal cancer growth via suppressing p21.

Authors:  Yuanyuan Gong; Zukai Liu; Yihang Yuan; Zhenzhen Yang; Jiawei Zhang; Qin Lu; Wei Wang; Chao Fang; Haifan Lin; Sanhong Liu
Journal:  Nat Commun       Date:  2022-03-25       Impact factor: 17.694

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.